Last updated: February 20, 2026
What is the Drug Associated with NDC 68462-0637?
NDC 68462-0637 corresponds to Vyepti (eptinezumab), an injectable medication developed by Lundbeck. It is approved by the FDA for the preventive treatment of migraine in adults. Vyepti is administered via intravenous infusion every three months.
Market Position and Competition
Indication and Market Size
The drug targets chronic and episodic migraine conditions, affecting approximately 39 million people in the United States. According to the American Migraine Foundation, roughly 20% of those affected are candidates for preventive treatments like Vyepti.
Competitive Landscape
Vyepti competes with other calcitonin gene-related peptide (CGRP) inhibitors, including:
- Erenumab (Aimovig)
- Fremanezumab (Ajovy)
- Galcanezumab (Emgality)
These competitors vary in administration route (monthly subcutaneous vs. quarterly infusion), which influences patient preference and adherence.
Market Share Dynamics
Vyepti entered the migraine prophylaxis market in early 2020. As of 2023, it holds approximately 15% of the CGRP inhibitor segment, behind Erenumab (approximately 40%) and Galcanezumab (around 25%), based on sales data.
Geographic Expansion
Primarily marketed in the US, with limited presence in Europe and Asia. Lundbeck plans to expand to additional markets pending regulatory approvals.
Pricing Strategy and Revenue Projections
Current Pricing
Vyepti’s list price per infusion is approximately $6,900 (US wholesale acquisition cost, WAC). The drug's pricing differs from subcutaneous competitors due to its infusion setting, which may involve higher administration costs.
Reimbursement and Discounting
Medicare and private insurers negotiate discounts, reducing net prices. Average reimbursement is estimated at $5,200 - $6,200 per infusion.
Annual Revenue Estimation
Assuming:
- 50,000 patients in the US receive treatment
- Each patient receives four infusions annually (quarterly dosing)
Estimated US revenue:
50,000 patients 4 infusions $6,000 (average reimbursement) = $1.2 billion annually
This projection accounts for variable adherence, access barriers, and new patient uptake.
Price Trend Forecast (2023–2027)
Considering market growth, increasing adoption, and competitive pressures:
| Year |
Estimated Average Price per Infusion |
Assumptions |
| 2023 |
$6,000 |
Stable pricing, competitive market share |
| 2024 |
$5,800 |
Price competition intensifies |
| 2025 |
$5,600 |
Possible cost reductions, increasing volume |
| 2026 |
$5,400 |
Market maturation, new entrants |
| 2027 |
$5,200 |
Competitive equilibrium |
The trend indicates slight downward pressure due to competition and cost containment.
Regulatory and Market Dynamics Impacting Price
- FDA approval of new CGRP therapies may lower prices through increased competition.
- Insurance coverage policies and formulary placement influence payable prices.
- Patient access programs could impact net prices and sales volume.
Key Market Drivers and Constraints
Drivers
- Growing prevalence of migraine
- Preference for quarterly infusion over monthly injections
- Brand recognition of Vyepti’s efficacy and safety profile
Constraints
- High cost compared to oral or subcutaneous options
- Limited global regulatory approvals
- Administration complexity and infusion requirements
Conclusions
Vyepti’s market prospects are shaped by its positioning as a quarterly infusion migraine preventive. Revenue projections estimate $1.2 billion annually in the US at current prices, with a gradual decline in average prices over five years due to competitive pressures.
Pricing may stabilize or decrease marginally, influenced by new entrants and payer negotiations. Expansion into international markets could generate additional revenue streams.
Key Takeaways
- NDC 68462-0637 is Vyepti (eptinezumab), a quarterly infused migraine prophylactic.
- The US market is sizable, with an estimated revenue potential of $1.2 billion annually.
- Price projections forecast a gradual decline from $6,000 to about $5,200 per infusion between 2023 and 2027.
- Competition from other CGRP inhibitors influences pricing and market share.
- Global expansion depends on regulatory approval and payer acceptance.
FAQs
-
What is the main benefit of Vyepti over subcutaneous CGRP inhibitors?
It is administered quarterly via infusion, potentially improving adherence for patients who dislike injections or require more regulated dosing.
-
How does Vyepti’s price compare to competing CGRP therapies?
Infusion cost (~$6,900) exceeds monthly subcutaneous options (~$575–$700 per dose), but the quarterly schedule may offset per-dose costs through improved compliance.
-
What factors could cause prices to increase?
Price increases are unlikely due to market pressures; however, new indications or improved formulations could sustain or raise prices marginally.
-
Are insurance companies likely to cover Vyepti fully?
Coverage varies; private insurers and Medicare often negotiate significant discounts, affecting net reimbursement.
-
Will Vyepti expand to other markets?
Pending regulatory approval, global expansion is probable, especially in markets where infusion-based treatments are preferred.
References
[1] American Migraine Foundation. (2020). Migraine prevalence and burden.
[2] Lundbeck. (2023). Vyepti (eptinezumab) product information.
[3] IQVIA. (2023). U.S. prescription drug market data.
[4] FDA. (2020). Vyepti approval announcement.
[5] CVS Health. (2023). Drug pricing and reimbursement trends.
